Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity
The TREAT Randomized Clinical Trial

Dylan A. Lowe, PhD; Nancy Wu, MS; Linnea Rohdin-Bibby, BA; A. Holliston Moore, PhD; Nisa Kelly, MS; Yong En Liu, BS; Errol Philip, PhD; Eric Vittinghoff, PhD; Steven B. Heymsfield, MD; Jeffrey E. Olgin, MD; John A. Shepherd, PhD; Ethan J. Weiss, MD

IMPORTANCE The efficacy and safety of time-restricted eating have not been explored in large randomized clinical trials.

OBJECTIVE To determine the effect of 16:8-hour time-restricted eating on weight loss and metabolic risk markers.

INTERVENTIONS Participants were randomized such that the consistent meal timing (CMT) group was instructed to eat 3 structured meals per day, and the time-restricted eating (TRE) group was instructed to eat ad libitum from 12:00 PM until 8:00 PM and completely abstain from caloric intake from 8:00 PM until 12:00 PM the following day.

DESIGN, SETTING, AND PARTICIPANTS This 12-week randomized clinical trial including men and women aged 18 to 64 years with a body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) of 27 to 43 was conducted on a custom mobile study application. Participants received a Bluetooth scale. Participants lived anywhere in the United States, with a subset of 50 participants living near San Francisco, California, who underwent in-person testing.

MAIN OUTCOMES AND MEASURES The primary outcome was weight loss. Secondary outcomes from the in-person cohort included changes in weight, fat mass, lean mass, fasting insulin, fasting glucose, hemoglobin A1c levels, estimated energy intake, total energy expenditure, and resting energy expenditure.

RESULTS Overall, 116 participants (mean [SD] age, 46.5 [10.5] years; 70 [60.3%] men) were included in the study. There was a significant decrease in weight in the TRE (−0.94 kg; 95% CI, −1.68 to −0.20; P = .01), but no significant change in the CMT group (−0.68 kg; 95% CI, −1.41 to 0.05, P = .07) or between groups (−0.26 kg; 95% CI, −1.30 to 0.78; P = .63). In the in-person cohort (n = 25 TRE, n = 25 CMT), there was a significant within-group decrease in weight in the TRE group (−1.70 kg; 95% CI, −2.56 to −0.83; P < .001). There was also a significant difference in appendicular lean mass index between groups (−0.16 kg/m²; 95% CI, −0.27 to −0.05; P = .005). There were no significant changes in any of the other secondary outcomes within or between groups. There were no differences in estimated energy intake between groups.

CONCLUSIONS AND RELEVANCE Time-restricted eating, in the absence of other interventions, is not more effective in weight loss than eating throughout the day.

TRIAL REGISTRATION ClinicalTrials.gov Identifiers: NCT03393195 and NCT03637855

© 2020 American Medical Association. All rights reserved.
The prevalence of overweight (body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 25 to 30) and obesity (BMI greater than 30) has increased dramatically recently¹ and is associated with increased risk for chronic diseases.² Even modest weight reduction can improve cardiovascular disease risk.³ However, long-term adherence to lifestyle changes is difficult. Therefore, it is important to find novel lifestyle-modification interventions that are (1) effective in reducing weight and (2) accessible and straightforward to enhance adherence.

Intermittent fasting (IF) has gained attention as a simple weight loss method. Intermittent fasting refers to eating windows separated by defined periods of fasting (>12 hours and up to 48 hours, or more). Most of the reported benefits of IF are either untested or undertested in humans.⁴ Time-restricted eating (TRE) is a specific IF protocol involving consistent fasting and eating periods within a 24-hour cycle.

Time restricted feeding (TRF) prevents weight gain in mice challenged with an isocaloric high-fat diet (HFD)⁵ and reduces weight and metabolic outcomes in already obese mice.⁶ Weight loss without a decrease in calorie intake suggests that TRF could affect energy expenditure to achieve a negative calorie balance.

Prior small studies in humans with overweight or obesity demonstrate that TRE can result in reduced calorie intake and is associated with a decrease in body weight and/or fat mass.⁷ ¹⁰ We conducted a randomized clinical trial (RCT) designed to determine the effect of TRE on weight and comprehensive metabolic outcomes in overweight and obese patients. We hypothesized that 8-hour TRE prescribed to individuals with overweight and obesity would lead to weight loss and improvements in metabolic markers compared with individuals following a standard 3-meals-per-day diet (consistent meal timing [CMT]).

Methods

Experimental Model and Participant Details

This study was conducted with approvals from the institutional review board (IRB) at the University of California, San Francisco (UCSF) and the University of Hawai’i Cancer Center (UHCC). The trial protocol is available in Supplement 1. The clinical trial was registered on ClinicalTrials.gov (NCT03393195).

Participants were recruited between August 2018 and June 2019 and data collection was completed in October 2019. Overall, 141 participants were enrolled in the study and were randomized. We randomized 25 participants for whom we never received any data. Data were collected from 116 participants; and 105 completed the 12-week protocol. The study was conducted on a custom mobile study application (app) on the Eureka Research Platform. Participants received study surveys through the study app. Participants were given a bluetooth weight scale to use daily, which was connected through the study app. Participants were randomized to 1 of 2 interventions. The study intervention only included recommendations to the timing of food intake (no recommendation for caloric and macronutrient intake or physical activity), and participants received daily reminders about their eating windows through the app. The CMT group was instructed to eat 3 structured meals per day. Snacking between meals was permitted. The TRE group was instructed to eat ad libitum from 12:00 PM until 8:00 PM and completely abstain from caloric intake from 8:00 PM until 12:00 PM the following day (16 hours fast:8 hours eat). Only water and black coffee or tea were permitted outside of the eating widow.

The IRB-approved protocol (Supplement) has minor discrepancies compared with the messages that the groups actually received, which were made on January 2, 2018, before any participants were enrolled in the trial. We reported this to the IRB and requested a retroactive review of an updated protocol. The IRB declined to provide retroactive review and approval citing that “while this does constitute a protocol deviation, it does not constitute a major violation and therefore does not meet our reporting requirements.” (Personal written communication. Kate Nolan, MPH, CIP, December 3, 2020). For clarification, the messages that were provided were as follows:

For the TRE group the initial instructions were as follows: “For this plan, you will be able to eat whatever you want between noon and 8:00 PM. However, from 8:00 PM until noon the following day, you can only drink water and black coffee or tea (no sugar or artificial sweeteners permitted):”

“If you experience drops in energy or have headaches, we suggest that you ease into it for the first few days by eating a small handful of nuts or other low-carbohydrate snacks (fat does not cause insulin to spike like carbohydrates and sugar do):”

“One day your body gets used to this new pattern, many people find that it gets much easier.”

“Try to follow this plan every day for 12 weeks.”

“Do not forget to weigh yourself and check your blood pressure every morning before you eat or drink coffee and to complete the short surveys. We will send you reminders if you forget.”

Using the Eureka mobile app, participants in this group received messages notifying them when they should be abstaining and when they were able to eat. These messages were: “Do not eat between 8:00 PM tonight and 12 noon tomorrow” for the restricted time period (message to appear at 8:00 PM); “do not eat until 12 noon today” (message appears at 8:00 AM); “It is okay to eat now until 8:00 PM tonight” (message appears at...
12:00 PM). They also received reminders to weigh themselves every Friday morning.

For the CMT group the control cohort was instructed to eat 3 meals per day (7:00 AM - 11:00 AM, 11:00 AM - 3:00 PM, 4:00 PM - 10:00 PM). The initial instructions were as follows: “For this eating plan, you will be instructed to eat breakfast between 7:00 AM and 11:00 AM each day. In addition, lunch will be consumed between 11:00 AM and 3:00 PM, and dinner will be consumed between 4:00 PM and 10:00 PM. If you are having trouble sticking to a regular meal schedule due to work and family obligations, it can help to prepare refrigerated or frozen meals in advance for busy days.”

“Light snacking will be permitted at any time to curb cravings so that you can wait to eat your next meal during the specified meal window.”

“Try to follow this plan every day for 12 weeks.”

“Do not forget to weigh yourself and check your blood pressure every morning before you eat or drink coffee and to complete the short surveys. We will send you reminders if you forget.”

To control for the effect of messaging, this group also received 3 messages as part of the control group: “Good morning! Just a friendly reminder to weigh yourself on your iHealth Scale and measure your blood pressure before you eat your first meal. Please eat your first meal before 11:00 AM today.” (message appeared at 8:00 AM); “Hello. Just a reminder to eat your second meal today before 3:00 PM.” (message appeared at 12:00 PM); “Good evening! Enjoy your last meal of the day before 10:00 PM tonight to help your metabolism while you sleep.” (message appeared at 6:00 PM).

Participants provided consent through the app, and received a $50 Visa gift card for participating in the study.

Weight Measurements
All participants received an iHealth Lite Bluetooth scale (Model HS4S) to use at home. Participant accounts were linked to the Eureka Research platform. Participants were instructed to use the scale daily in the morning before eating or drinking and prior to structured physical activity.

In-Person Metabolic Testing
Participants who lived within 60 miles of UCSF were eligible to undergo extensive in-person metabolic testing at the UCSF Clinical Research Center and the UCSF Body Composition Laboratory as detailed by Ng et al.13 Enrollment was capped at 50 participants, and 50 participants opted into the in-person testing. A total of 46 participants completed all 4 in-person visits.

Statistical Analysis
The statistical analysis plan is available in Supplement 2. The primary outcome was change in weight since baseline, measured daily via iHealth scales, in the overall cohort of 116 participants. To estimate the intention-to-treat effect of treatment assignment, we used a linear mixed model with fixed effects for treatment assignment, days since baseline, and their interaction, and random effects for participant and day, with unstructured covariance matrix, accommodating any nonlinearity in the trajectories using 3-knot cubic splines. The treatment effect was estimated by the fitted between-group difference at day 90, net of any baseline difference. In sensitivity analyses, we repeated the analysis after Winsorizing outliers, which was defined as points more than 1.5 times the interquartile range below the 25th or above the 75th percentile of the overall distribution. No adjustments were made to P values or confidence intervals for multiple comparisons for the primary outcome.

Results
Of the 141 participants who were randomized to 1 of the 2 interventions, 105 (74.5%) completed the entire 12-week intervention (Figure 1). Of the 36 randomized participants who did not complete the study, 25 never recorded weight measurements (TRE n = 10, CMT n = 15), 8 were lost to follow-up (TRE n = 7, CMT n = 1), and 3 discontinued intervention (TRE n = 2, CMT n = 1). Participants had a mean (SD) age of 46.5 (10.5) years and a mean (SD) weight of 99.2 (16.0) kg (Table 1).

Self-reported adherence to the diets was 1002 of 1088 (92.1%) in the CMT group (did not miss any meals) and 1128 of 1351 (83.50%) in the TRE group (ate only within the 8-hour window) (Figure 2A).

Of the 141 participants randomized in the study, we invited persons living within 60 miles of San Francisco (enrollment was first come, first served and was capped at 50) to undergo comprehensive in-person metabolic testing (referred to as in-person cohort). Overall, 46 of 50 participants completed the entire in-person testing protocol (CMT n = 24, TRE n = 22). Baseline characteristics of both cohorts are shown in Table 1.

Weight
There was a significant decrease in weight in the TRE group (−0.94 kg; 95% CI, −1.68 kg to −0.20 kg; P = .01) and a nonsignificant decrease in weight in the CMT group (−0.68 kg; 95% CI, −1.41 kg to 0.05 kg; P = .07). Importantly, there was no significant difference in weight change between groups (−0.41%; 95% CI, −1.30 kg to 0.78 kg; P = .63) (Figure 2, B and C) (Table 2). There was a significant decrease in percentage of baseline weight in the TRE group (−1.17%; 95% CI, −1.89% to −0.45%; P = .002) and in the CMT group (−0.75%; 95% CI, −1.47% to −0.04%; P = .04); however, there was no significant difference between groups (−0.41%; 95% CI, −1.43% to 0.60%; P = .43) (Table 2). There were no statistically significant changes in estimated energy intake or energy expenditure between groups (eFigure 1A and 1B in Supplement 3).

In the in-person cohort (n = 50), there was a significant decrease in weight in the TRE group using the in-person weight measurements (−1.70 kg; 95% CI, −2.56 kg to −0.83 kg; P < .001) but not in the CMT group (−0.57 kg; 95% CI, −1.40 kg to 0.26 kg; P = .18) (Table 3) (eFigure 2 in Supplement 3). There was a nonsignificant difference in weight loss between groups (−1.13 kg; 99.7% CI, −2.33% to 0.07%; P = .07) (Table 3). There was a significant decrease in percentage of baseline weight in the TRE group (−1.81%; 95% CI, −2.85% to 0.78%; P < .001) but not in...
the CMT group (−0.65%; 95% CI, −1.64% to 0.34%; \(P = .19\)) or between groups (−1.16%; 95% CI, −2.59% to 0.27%; \(P = .11\)). There was strong agreement between in-person weight measurements and at-home weight measurements as determined by a Bland-Altman analysis (eFigure 3 in Supplement 3).

### Body Composition and Energy Expenditure

As measured by dual-energy x-ray absorptiometry (DXA), there was no significant change in whole body fat mass (FM) in the TRE (−0.51 kg; 95% CI, −1.17 kg to 0.15 kg; \(P = .13\)) or the CMT groups (−0.03 kg; 95% CI, −0.66 kg to 0.60 kg; \(P = .93\)), and there was no significant difference between groups (−0.48 kg;...
There was a significant decrease in lean mass (calculated as fat-free mass minus bone mineral content) in the TRE (−1.10 kg; 95% CI, −1.73 kg to −0.48 kg; \( P < .001 \)) but not in the CMT group (−0.35 kg; 95% CI, −0.95 kg to 0.25 kg; \( P = .25 \)). The difference in lean mass between groups (−0.75 kg; 95% CI, −1.96 kg to 0.45 kg; \( P = .09 \)) was not statistically significant. Appendicular lean mass (ALM) was decreased significantly in the TRE group (−0.64 kg; 95% CI, −0.89 kg to −0.39 kg; \( P < .001 \)) but not in the CMT group (−0.17 kg; 95% CI, −0.41 kg to 0.07 kg; \( P = .16 \)). There was a significant difference in ALM between groups (−0.47 kg; 95% CI, −0.82 kg to −0.12 kg; \( P = .009 \)). There was a significant decrease in appendicular lean mass index (ALMI) in the TRE group (−0.22 kg/m²; 95% CI, −0.30 kg/m² to −0.14 kg/m²; \( P < .001 \)) but not in the CMT group (−0.06 kg/m²; 95% CI, −0.14 kg/m² to 0.02 kg/m²; \( P = .14 \)). The difference in ALMI between groups was also significant (−0.16 kg/m²; 95% CI, −0.27 kg/m² to −0.05 kg/m²; \( P = .005 \)). Trunk lean mass significantly decreased in the TRE group (−0.47 kg; 95% CI, −0.88 kg to −0.06 kg; \( P = .02 \)). There was no significant change in trunk lean mass in the CMT group (−0.15 kg; 95% CI, −0.54 kg to 0.24 kg; \( P = .45 \)) or between groups (−0.32 kg; 95% CI, −0.89 kg to 0.25 kg; \( P = .27 \)). For a comprehensive list of all body composition variables analyzed, see eTable 2 in Supplement 3.

Respiratory quotient (RQ) did not change significantly in the TRE group (0.01; 95% CI, −0.02 to 0.03; \( P = .82 \)); RQ
<table>
<thead>
<tr>
<th>Variable</th>
<th>Preintervention (n = 25)</th>
<th>ΔTRE (n = 25)</th>
<th>P-value</th>
<th>ΔTRE P-value</th>
<th>ΔTRE ΔMT P-value</th>
<th>ΔTRE ΔMT ΔP-value</th>
<th>ΔTRE ΔMT ΔP-value</th>
<th>ΔTRE ΔMT ΔP-value</th>
<th>ΔTRE ΔMT ΔP-value</th>
<th>ΔTRE ΔMT ΔP-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight, kg</td>
<td>93.0</td>
<td>92.4</td>
<td>.07</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight change, %</td>
<td>−0.65</td>
<td>0.11</td>
<td>.11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fat mass, %</td>
<td>32.9</td>
<td>31.4</td>
<td>.002</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subcutaneous</td>
<td>1.62</td>
<td>1.61</td>
<td>.99</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trunk fat mass, %</td>
<td>−0.35</td>
<td>−0.28</td>
<td>.10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Appendicular</td>
<td>27.1</td>
<td>26.7</td>
<td>.35</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lean mass, kg</td>
<td>23.6</td>
<td>23.3</td>
<td>.74</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone mass, g</td>
<td>1.66</td>
<td>1.68</td>
<td>.67</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Handgrip strength, kg</td>
<td>30.8</td>
<td>30.9</td>
<td>.99</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Energy expenditure, kcal/d</td>
<td>2772.1</td>
<td>2500.4</td>
<td>.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Energy expenditure, kcal/kg</td>
<td>244.7</td>
<td>210.4</td>
<td>.18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** All data are presented as means (95% CI). For secondary outcome measures, Bonferroni-corrected confidence intervals are presented and Bonferroni-adjusted critical α of 0.006 is used. For data with statistical outliers, Winsorised data was used to generate values.
increased in the CMT group (0.03; 95% CI, 0.01 to 0.06; \(P = .003\)), but there was no significant difference between groups (−0.03; 95% CI, −0.06 to −0.01, \(P = .06\)). There was no significant difference in resting metabolic rate (RMR) in the TRE (−28.1 kcal/d; 95% CI, −91.8 kcal/d to 35.5 kcal/d; \(P = .39\)) or the CMT group (−43.15 kcal/d; 95% CI, −104.2 kcal/d to 18.0 kcal/d; \(P = .17\)), and there was no significant difference between groups (15.0 kcal/d; 99.7% CI, −108.1 kcal/d to 138.0 kcal/d; \(P = .74\)) (Table 3). There was a significant decrease in total energy expenditure (TEE) in both groups (TRE: −177.9 kcal/d; 95% CI, −259.2 kcal/d to −69.9 kcal/d; \(P = .003\)) but there was no significant difference between groups (−0.03; 95% CI, −0.06 to −0.01, \(P = .39\)) or between groups (−1.08 mm Hg; 95% CI, −23.9 kcal/d to −23.9 kcal/d; \(P = .92\)). There was no significant difference between groups (−50.6 kcal/d; 99.7% CI, −259.2 kcal/d to 15.1 kcal/d; \(P = .51\)).

Blood Lipids, Glucose, Insulin, and Cardiometabolic Health Markers

There were no significant within-group or between-group differences in fasting glucose, fasting insulin, HOMA-IR, HbA1C, triglycerides, total cholesterol, LDL, or HDL levels (eTable 1 in Supplement 3). However, our walking data revealed significant changes in sleep efficiency, sleep latency, and awake time in the TRE group and between groups (eTable 6 in Supplement 3).

There was no significant difference in systolic blood pressure in the TRE group (−4.08 mm Hg; 95% CI, −17.13 mm Hg to 9.00 mm Hg; \(P = .43\)), but there was a significant change in diastolic blood pressure in the TRE group (−2.67 mm Hg; 95% CI, −4.95 mm Hg to −0.40 mm Hg; \(P = .02\)) (Table 3). There was a significant decrease in diastolic blood pressure (2.17 mm Hg; 95% CI, −3.18 mm Hg to 7.52 mm Hg; \(P = .43\)) and in the CMT group (−0.11 mm Hg; 95% CI, −0.69 mm Hg to 0.49 mm Hg; \(P = .71\)).

Sleep Quality Activity Tracking and Food Attitudes

There were no significant changes in any of the self-reported sleep measures in either group or between groups in the total cohort (eTable 5 in Supplement 3). However, Oura ring data revealed significant changes in sleep efficiency, sleep latency, and awake time in the TRE group and between groups (eTable 6 in Supplement 3).

The Oura ring data also revealed a significant reduction in daily movement in the TRE group (−2102.14 au; 95% CI, −3162.54 au to −1041.73 au; \(P < .001\)) and between groups (−1673.44 au; 95% CI, −2311.14 au to −135.70 au; \(P = .03\)) but not in the CMT group (−428.70 au; 95% CI, −1542.25 au to 684.85 au; \(P = .51\)). There was a significant decrease in step count in the TRE group (−2498.89 steps; 95% CI, −3999.91 to −1057.88; \(P < .001\)) and between groups (−2241.41 steps; 95% CI, −4320.51 to −1623.1; \(P = .04\)) but not in the CMT group (−257.48 steps; 95% CI, −1756.20 to 1241.23; \(P = .74\)). The correlation between change in step count and change in TEE was 0.52 in the TRE group and 0.03 in the CMT group, but the 2 correlations did not differ significantly (eFigure 4 in Supplement 3).

Discussion

The TRE is attractive as a weight-loss option in that it does not require tedious, and time-consuming methods such as calorie-counting or adherence to complicated diets. Indeed, we found that self-reported adherence to the TRE schedule was high (Figure 2A); However, in contrast to our hypothesis, there was no greater weight loss with TRE compared with the CMT. In addition, we found among our secondary outcomes that there were few differences between the 2 groups. Specifically, there were no significant differences in fat mass, fasting insulin, glucose, HbA1C, or blood lipids between the TRE and CMT groups.

Most humans eat throughout their waking hours.12 We prescribed an 8-hour eating window and did not prescribe calorie or macronutrient guidance so as to offer a simple, real-world recommendation to free-living individuals. We chose a 12 PM to 8 PM eating window because we reasoned that people would find it easier culturally to skip breakfast than dinner—a more social meal in most cultures.

Our results are consistent with a prior study demonstrating that a recommendation to skip breakfast does not affect weight outcomes in patients trying to lose weight13 but, contrast previous reports describing the beneficial effects of TRE on weight loss and other metabolic risk markers.7,10,14,15 Wilkinson et al11 found that TRE was associated with an approximately 3% weight loss and improvements in cardiovascular risk markers in patients with Metabolic Syndrome. This single-arm study was small (n = 19) and, importantly, did not have a control group.

Although the prescribed (12-8 PM) eating window is likely more attractive and more amenable to long-term adherence, it might not be optimal for the metabolic advantages of TRE. Sutton et al11 performed a 5-week RCT comparing early TRE (eTRE: 6-hour eating window with dinner before 3:00 PM) to a control diet (12-hour eating window). They found improved glycemic control and improvements in cardiovascular risk markers without changes in body weight in the eTRE group.

In analysis of secondary outcomes, we found a significant reduction in lean mass in the TRE group. In the in-person cohort, the average weight loss in the TRE group was 1.70 kg. Of this, 1.10 kg (approximately 65% of weight lost) was lean mass; only 0.51 kg of weight loss was fat mass. Loss of lean mass during weight loss typically accounts for 20% to 30% of total weight loss.16-22 The proportion of lean mass loss in this study (approximately 65%) far exceeds the normal range of 20% to 30%.22 In addition, there was a highly significant between-group difference in ALM. Appendicular lean mass is correlated with nutritional and physical status, and reduced ALM can lead to weakness, disability, and impaired quality of life.23-26 This serves as a caution for patient populations at risk for sarcopenia because TRE could exacerbate muscle loss.27 Finally, the extent of lean mass loss during weight loss has been positively correlated with weight regain.28

The effect of TRE on lean mass is largely unexplored. Prior studies show that TRE prevents gains in lean mass.29 A follow-up study showed that when calorie intake and protein intake were matched to prestudy consumption, no change in lean mass was seen.5,30
mass was observed.30 An RCT comparing TRE in overweight and obese patients demonstrated a significant loss of lean mass compared with controls, but no significant change in fat loss between groups.31 Ad libitum feeding during TRE leads to reduced calorie intake and might also reduce protein intake.9 Together, these data highlight the importance of adequate protein consumption while adhering to a TRE diet. Many studies have shown that adequate/excessive protein consumption during weight loss can mitigate losses in lean mass.16,28,32-35 National Health and Nutrition Examination Survey data show that most daily protein intake occurs during meals, and snacking accounts for a small portion of total daily protein intake.36 The loss of ALM during TRE could be mitigated by increasing the number of meals within the eating window or consuming protein supplements.16,28 Timing of protein consumption may also play a role in changes in lean mass.37-39

Strengths and Limitations

Strengths of the study include randomization, an easy to follow, real-world prescription-based intervention, and an appropriate control group. Although there was statistically significant weight loss in the TRE group, there was no difference between groups. This indicates that participation in a weight loss study alone (even in the control group) is sufficient to lead to short-term weight loss and highlights the importance of including a control arm in weight loss studies.

A limitation is we do not have self-reported measures of energy or macronutrient intake. Although we did not measure calorie intake, mathematical modeling of changes in energy intake suggests that calorie intake did not significantly differ between groups. This model has been validated to be more accurate than self-reported energy intake.40,41 We did not measure changes in protein intake. Given the loss of ALM in participants in the TRE arm and previous reports of decreased protein consumption from TRE,9,28 it is possible that protein intake was altered by TRE in this cohort, and this clearly warrants future study. Finally, the DXA analysis of lean mass did not factor in muscle hydration, so it is possible that changes in hydration could confound the lean mass calculations. To help control for this, participants fasted for more than 12 hours and voided their bladder prior to DXA scans. The change in lean mass in the TRE group was much greater than the loss of body water, so it is unlikely that differences in muscle hydration would account for all of the lean mass loss.

Conclusions

In this RCT, a prescription of TRE did not result in weight loss when compared with a control prescription of 3 meals per day. Time-restricted eating did not change any relevant metabolic markers. Finally, there was a decrease in ALM in the TRE group compared with CMT. Together, the results of this study (1) do not support the efficacy of TRE for weight loss, (2) highlight the importance of control interventions, and (3) offer caution about the potential effects of TRE on ALM. Future studies should be aimed at understanding the effects of early vs late TRE and protein intake or timing as a means to offset the loss in ALM.

ARTICLE INFORMATION

Accepted for Publication: July 6, 2020.
Correction: This article was corrected on November 2, 2020, to fix an error in panel C of Figure 2. The y-axis labels were incorrect and the data on the right side of the panel were incorrectly aligned. It was corrected again on February 22, 2021, to correct pervasive data errors in the Methods section.

Author Contributions: Drs Weiss had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Lowe, Moore, Olgin, Weiss. Acquisition, analysis, or interpretation of data: Lowe, Wu, Rohdin-Bibby, Kelly, Liu, Phillip, Vittinghoff, Heymsfield, Olgin, Shepherd, Weiss. Drafting of the manuscript: Lowe, Phillip, Olgin, Weiss. Critical revision of the manuscript for important intellectual content: Lowe, Wu, Rohdin-Bibby, Moore, Kelly, Liu, Vittinghoff, Heymsfield, Olgin, Shepherd, Weiss. Statistical analysis: Vittinghoff, Olgin, Weiss. Obtained funding: Lowe, Heymsfield, Olgin, Shepherd, Weiss. Administrative, technical, or material support: Lowe, Wu, Rohdin-Bibby, Moore, Kelly, Liu, Phillip, Heymsfield, Olgin, Weiss. Supervision: Lowe, Olgin, Shepherd, Weiss.

Conflict of Interest Disclosures: Dr Lowe reported personal fees from Keyto outside the submitted work. Dr Vittinghoff reported personal fees from UCSF during the conduct of the study. Dr Heymsfield reported personal fees from Medifast Medical Advisory Board and personal fees from Tanita Medical Advisory Board outside the submitted work. Dr Weiss reported grants from NIH, grants from James Peter Read Foundation, nonfinancial support from Mocacare Inc, and nonfinancial support from Ihealth Labs during the conduct of the study; he also is a co-founder and equity stake holder of Keyto, Inc; and owns stock and was formerly on the board of Virta, Inc. No other disclosures were reported.

Funding/Support: This research was funded by the University of California, San Francisco, Cardiology Division’s Cardiology Innovations Award Program and the National Institute of Diabetes and Digestive and Kidney Diseases (NIH ROI DK109008). Additional support came from the James Peter Read Foundation. Bluetooth connect scales were graciously gifted from IHealth Labs Inc. MOCACuff blood pressure cuffs were gifted from MOcacare. Health tracking rings were gifted from Oura.

Role of the Funder/Sponsor: The University of California, San Francisco had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank Kevin Hall, PhD, National Institute of Diabetes and Digestive and Kidney Diseases, for critical reading of the manuscript and for providing software for calculation of energy intake. We also thank Juen Guo, National Institute of Diabetes and Digestive and Kidney Diseases, for providing software for calculation of energy intake.


REFERENCES

5. Hatori M, Vollmers C, Zarrinpar A, et al. Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a...